We compared acute gastroenteritis (AGE)-related hospitalization rates among children <5 years of age during the prerotavirus vaccine (2000)(2001)(2002)(2003)(2004)(2005)(2006) and post-rotavirus vaccine (2008)(2009)(2010)(2011)(2012)(2013) periods to estimate national reductions in AGErelated hospitalizations and associated costs. We estimate that between 2008 and 2013, AGE-related hospitalizations declined by 382 000, and $1.228 billion in medical costs were averted.
Before the introduction of rotavirus vaccines in the United States, rotavirus gastroenteritis resulted in an estimated 20 to 60 deaths, 55 000 to 70 000 hospitalizations, 200 000 emergency department visits, and nearly 500 000 outpatient visits among children aged <5 years annually [1] . In February 2006, the Advisory Committee on Immunization Practices (ACIP) recommended the routine use of pentavalent rotavirus vaccine (RotaTeq, Merck and Co., Whitehouse Station, NJ) for US infants [1] . In June 2008, the ACIP updated its recommendations to include the use of monovalent rotavirus vaccine (Rotarix, GSK Biologicals, Rixensart, Belgium) [2] .
Since the introduction of rotavirus vaccines, rates of hospitalization in US children for acute gastroenteritis (AGE) and rotavirus have decreased substantially [3] [4] [5] . We previously described reductions in diarrhea-and rotavirus-associated hospitalization rates in US children after rotavirus vaccine introduction [4] . We now extended this analysis to include an additional year of data and we estimate the national reductions in the absolute number of all-cause AGE in US children <5 years of age as well as reductions in health care costs after rotavirus vaccine introduction.
METHODS
We analyzed data from the State Inpatient Databases of the Healthcare Cost and Utilization Project (HCUP), produced by the Agency for Healthcare Research and Quality (AHRQ). The State Inpatient Databases component of the HCUP captures data on all hospitalizations that occur in community and academic hospitals in the participating states [6] . This study was conducted through an active collaboration between the Centers for Disease Control and Prevention and the AHRQ. The study did not require review by an institutional review board, because deidentified aggregated data were used.
All discharges from short-stay AGE-related hospitalizations were identified by using the [3, 4] . Rotavirus-coded hospitalizations were identified by using the rotavirus-specific ICD-9-CM code 008.61. We restricted the rate-reduction analyses to data from 26 states that consistently provided hospitalization data to the HCUP each year during the study period from 2000 to 2013. These states include Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Iowa, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Missouri, North Carolina, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Utah, Washington, Wisconsin, and West Virginia. Approximately 74% of US children aged <5 years resided in 1 of these 26 states [7] . Hospitalization rates were calculated by dividing the annual number of hospitalizations by the number of children <5 years of age who resided in the 26 participating states during that year using the National Center for Health Statistics bridgedrace population estimates for 2000 through 2013 as the denominator [7] .
To compare the relative difference in hospitalization rates for AGE and rotavirus before and after rotavirus vaccine licensure, we compared the mean hospitalization rate for calendar years 2000 to 2006 with that for calendar years 2008 to 2013, respectively. Data from 2007 were excluded, because rotavirus vaccine coverage rates were low and uneven in the first year after vaccine introduction. Statistical comparisons of rates, rate reductions, and 95% confidence intervals for rate reductions were calculated using Poisson regression analysis. To obtain nationally representative estimates of the annual number and cost of AGE-related hospitalizations, we applied the annual rates to the entire US population of children <5 years of age according to US census data [7] .
To calculate the annual reductions, we subtracted the annual number and costs of hospitalizations in each postvaccine year from the mean prevaccine (2000-2006) data. The median cost of a hospitalization for AGE was obtained after converting hospital charges to costs by using the cost-to-charge ratio file for the 2010 Nationwide Inpatient Sample database [8] . The total costs of prevented hospitalizations were calculated by multiplying the estimated number of AGE-related hospitalizations prevented by the median cost of such hospitalizations.
RESULTS
We examined 1 253 951 AGE-related hospitalizations among children <5 years of age during 2000 to 2013, 203 616 (16%) of which were coded as a rotavirus-related hospitalization. The mean annual prevaccine AGE-related hospitalization rate among children <5 years of age was 76 per 10 000 (annual range, 73 per 10 000 to 83 per 10 000). AGE-related hospitalization (Figure 1) . AGErelated hospitalization rates in the postvaccine years were reduced by 31% to 55%, and greater reductions were documented in later years (Table 1) . Furthermore, a biennial pattern emerged in the postvaccine years; lower and delayed rotavirus seasonal peaks in 2008, 2010, and 2012 were found, and we observed slightly higher and earlier peaks in 2009, 2011, and 2013 ( Figure 1) . In 2013, the AGE-related hospitalization rate was slightly higher than that in 2012, which represents a high year in the biennial pattern.
We estimate that the annual number of AGE-related hospitalizations among children <5 years of age in the United States declined from an average of 148 912 during the prevaccine years to a nadir of 68 633 in 2012 (Table 1 ). An estimated 382 858 hospitalizations were averted from 2008 to 2013 (average annual number of hospitalizations averted, 63 810).
The median cost for an AGE-related hospitalization was $3210. Before vaccine introduction, the average annual cost for AGE-related hospitalizations in the United States was $478 million. The annual cost reductions after rotavirus vaccine introduction ranged between $134 million and $257 million, and an estimated $1.228 billion was saved from 2008 to 2013 (annual average AGE-related hospitalization costs averted, $204 million).
DISCUSSION
The introduction of routine rotavirus vaccination in 2006 was followed by substantial reductions in the rate of AGE-related hospitalizations. We estimate that since the introduction of rotavirus vaccines in the United States in 2006, 382 000 hospitalizations in children <5 years of age were averted, which results in $1.228 billion saved in direct hospitalization costs. Our results provide additional information that supports the effect that the implementation of rotavirus vaccines exerted on AGE-associated morbidity and costs in the United States.
Before rotavirus vaccine implementation, a mature rotavirus vaccination program was estimated to avert 34 000 to 44 000 hospitalizations in US children aged <5 years annually [9, 10] . Although these estimates were based on population sizes in the 1990s to early 2000s, our figure of ~80 000 hospitalizations averted during the most recent years of 2012 to 2013 substantially exceeds expected reductions. A potential explanation is that pre-vaccine-introduction studies underestimated the burden of rotavirus-related hospitalizations in US children, because these figures were derived either by using indirect approaches such as measuring excess winter seasonal hospitalizations or by using rotavirus-surveillance data from an active surveillance study conducted in a single city in the 1980s that showed that rotavirus accounted for approximately one-third of AGE-related hospitalizations. A more recent active surveillance study conducted in 3 US counties during the period immediately preceding rotavirus vaccine implementation revealed that rotavirus accounted for almost half of all AGE-related hospitalizations during the months of January to June, and this figure is in line with the reductions we observed in the postvaccine years [11] . Also, studies have found that rotavirus vaccination confers indirect benefits to unvaccinated children (via herd immunity), which is a phenomenon that might have amplified the potential effect of vaccination [5] .
Our study had some limitations. First, although the rotavirus ICD-9-CM code has been shown to be specific for identifying laboratory-confirmed rotavirus hospitalizations, rotavirus-coded events underestimate the true burden of rotavirus-related hospitalizations because laboratory testing and coding for rotavirus are not performed routinely for all patients with gastroenteritis [12] . Thus, we relied on all AGE-related hospitalizations to estimate national reductions in hospitalizations and costs after rotavirus vaccine introduction. Although trends in AGE-related hospitalizations could be affected by secular changes in the incidence of other pathogens such as norovirus, the pattern of greater declines in more recent years with higher rotavirus vaccine coverage supports the theory that the reductions are related primarily to rotavirus vaccination. Our cost-reduction assessment did not include office or emergency department visits, most professional fees, or noncovered charges during hospitalization. Moreover, indirect costs to households in excess of hospital charges paid out of pocket (eg, time loss, transportation, etc) were not included. Therefore, our report underestimates the overall cost savings associated with rotavirus vaccine introduction. Rotavirus-associated deaths are uncommon in the United States, and reporting through the HCUP might miss some cases, because only in-hospital diarrhea-related deaths in children tested for rotavirus would be captured. We could not estimate the effect that rotavirus vaccines had on reduction in the numbers of these deaths. Last, there was potential bias resulting from restricting the analyses to 26 states with consistent reporting; however, these 26 states account for almost three-fourths of the US birth cohort, so major bias is unlikely.
In conclusion, rotavirus vaccine introduction in the United States has resulted in a substantial decline in AGE-related hospitalizations along with their associated costs. An expansion of this cost-savings analysis to include household and professional costs would enable updated cost-effectiveness estimates for routine use of rotavirus vaccines in the United States. 
